A Retrospective Observational Descriptive Study on the Effectiveness and Usage of Emicizumab and Antihemophilic Factor (recombinant), Fc Fusion Protein in Patients with Hemophilia A in the US

被引：0
|
作者：
Cockerham, Alex [1 ]
Wilson, Amanda [2 ]
Frick, Andrew [3 ]
Dasmahapatra, Pronabesh [2 ]
机构：
[1] Sanofi, Brookline, MA USA
[2] Sanofi, Cambridge, MA USA
[3] Trio Hlth, San Diego, CA USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-148325
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3031
引用
下载
收藏
页数：4
相关论文
共 50 条
  • [41] Extended Half-Life of the Double-Chain Recombinant Factor VIII-Fc Fusion Protein (FRSW107) in Hemophilia a Patients
    Xue, Feng
    Sun, Jing
    Chen, Yun
    Zhang, Xinsheng
    Sun, Haiyan
    Wang, Yali
    Yang, Renchi
    BLOOD, 2019, 134
  • [42] MANAGED CARE ORGANIZATION BUDGET IMPACT OF ADDING RECOMBINANT FACTOR VI FC FUSION PROTEIN (RFVIIIFC) TO THE FORMULARY FOR THE TREATMENT OF HEMOPHILIA A
    Buckley, B. C.
    Livingston, T. P.
    Eldar-Lissai, A.
    Hall, E. C.
    VALUE IN HEALTH, 2015, 18 (03) : A294 - A294
  • [43] Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Subjects With Severe Hemophilia A: Expanded to Include Pediatric Subjects
    Katragadda, Suresh
    Neelakantan, Srividya
    Diao, Lei
    Wong, Nancy
    JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (07): : 889 - 900
  • [44] Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A
    Zhao, Yongqiang
    Hu, Yu
    Jin, Jie
    Zhao, Xielan
    Wang, Xuefeng
    Wu, Runhui
    Wu, Depei
    Yang, Renchi
    Yang, Feng'e
    Hu, Qun
    Wang, Juan
    Fang, Hai
    Engl, Werner
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2021, 27
  • [45] Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B
    Ducore, Jonathan M.
    Miguelino, Maricel G.
    Powell, Jerry S.
    EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (05) : 559 - 571
  • [46] Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study
    Oldenburg, Johannes
    Hay, Charles R. M.
    Jimenez-Yuste, Victor
    Peyvandi, Flora
    Schved, Jean-Francois
    Szamosi, Johan
    Winding, Bent
    Lethagen, Stefan
    BMJ OPEN, 2019, 9 (05):
  • [47] Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice
    Toby, Garabet G.
    Liu, Tongyao
    Yang Buyue
    Zhang, Xin
    Bitonti, Alan J.
    Pierce, Glenn F.
    Sommer, Jurg M.
    Jiang, Haiyan
    Peters, Robert T.
    PLOS ONE, 2016, 11 (02):
  • [48] Pharmacokinetics Of Recombinant Factor IX Fc Fusion Protein (rFIXFc) In Pediatric Subjects With Hemophilia B: A Interim Analysis Of The Kids B-LONG Study
    Fischer, Kathelijn
    Kulkarni, Roshni
    Bradbury, Myles
    Ragni, Margaret V.
    Rangarajan, Savita
    Dong, Yingwen
    Li, Shuanglian
    Jiang, Haiyan
    Nugent, Karen
    Pierce, Glenn F.
    Allen, Geoffrey
    BLOOD, 2013, 122 (21)
  • [49] Cost-effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States
    Potnis, Kunal C.
    Viswanathan, Giri
    Bona, Robert D.
    Ito, Satoko
    Kempton, Christine L.
    Pandya, Ankur
    Krumholz, Harlan M.
    Goshua, George
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (09) : E247 - E250
  • [50] PHARMACOKINETIC-GUIDED PROPHYLAXIS WITH RECOMBINANT ANTIHEMOPHILIC FACTOR IMPROVES BLEEDING RATES IN PATIENTS WITH MODERATE HEMOPHILIA: REAL-WORLD OBSERVATIONAL DATA FROM THE AHEAD GERMAN STUDY
    Klamroth, R.
    Kurnik, K.
    Wenning, S.
    Escuriola-Ettingshausen, C.
    Regensburger, S.
    Tang, L.
    Gu, J.
    Guerra, R.
    Oldenburg, J.
    HAEMOPHILIA, 2022, 28 : 79 - 80
12345